Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

Highlights Include:

-- Results demonstrating that TYKERB and trastuzumab together resulted in a clinically meaningful extension of progression-free survival (PFS)

-- Combining TYKERB and trastuzumab to attack both the inside and outside of the HER2 receptor may create a more complete HER2 blockade

-- Data demonstrating activity of TYKERB alone despite patients' previous treatment with multiple lines of trastuzumab and chemotherapy

LONDON and PHILADELPHIA, May 16 /PRNewswire-USNewswire/ -- GlaxoSmithKline today announced positive data from the first-ever randomized, multi-center, open label Phase III trial of the combination of two targeted agents, TYKERB and trastuzumab, in women with HER2-positive metastatic breast cancer (1). HER2-positive breast cancer is a particularly aggressive form of cancer that affects approximately 25 to 30 percent of breast cancer patients (2). The study results demonstrated a benefit from the combination. Both treatments target the HER2 (ErbB2) protein but work in different ways (1). Trastuzumab attaches to the outside of the HER2 protein, while TYKERB goes inside the cell to block signals from the HER2 protein for the cancer to grow (3). GlaxoSmithKline Oncology will present these and other new data in breast cancer at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago beginning Friday, May 30th.

"Many women with HER2 positive breast cancer are still very active and living full lives, yet when their disease progresses after trastuzumab and chemotherapy, we have had limited treatment options. Therefore it is important to study options that may eventually help women in their fight against this disease," said lead investigator Joyce O'Shaughnessy, M.D., Baylor-Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas, TX. "Effectively attacking HER2 from multiple angles is an exciting and innovative approach, and demonstrates the significant advances being achieved in t
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 2012  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... present a company update at the J.P. Morgan Healthcare Conference ... a.m. PT.  Interested parties may access a ... section of the BioMarin website, www.BMRN.com .  A replay ...
... UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") ... Balance Sheet over the last twelve months, as referenced ... the Year ended September 30, 2011. In the report ... notes and accounts payable, decreased to $284,636, a 59% ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan Healthcare Conference 2UV Flu Technologies Aggressively Paying Down Debt to Build Platform for Expected Growth in Consumer and Hospital Markets 2UV Flu Technologies Aggressively Paying Down Debt to Build Platform for Expected Growth in Consumer and Hospital Markets 3
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... loss to Argentina in a World Cup match in 1998 ... by 27 per cent. The fact that extreme stress and ... known to almost everyone.However, research carried out at the ... Argentina during the 1998 World Cup has provided further evidence ...
... The number of people suffering from spine problems is on ... disc and spinal canal stenosis. Herniated disc is more common ... spinal canal stenosis is common among// older people. Hitherto, both ... an incision of about 12cms to be made and the ...
... of the main concerns of teenagers heading back to school ... UT Southwestern Medical Center say that stress is one of ... stress produces increased secretion of the hormone androgen //which results ... likely to suffer from acne due to the hormonal changes ...
... new study involving twenty mothers and their full-term infants, ... regular sleep cycle. ,Dr. Sari Goldstein from Tel ... the perinatal // period helps infants coordinate their circadian ... clock that helps humans and other beings adjust to ...
... shown that smoking leads to damage of the protective reflexes ... from flowing back into the hroat and smoking causes damage ... chords if fluid enters the area, a condition known as ... by imaging the relex area before and after cigarettes. The ...
... study on both mice and humans are showing why some people ... that if you eat a fatty meal or snack - a ... cholesterol you absorb is strongly influenced by your genes. Experts know ... high fat diet is bad for you. But little has been ...
Cached Medicine News:
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... The procedure follows the basic principle ... is competition between an unlabeled antigen and ... binding sites of a specific antiserum . ... biotin-labelled estrone) bound to the antibody is ...
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Medicine Products: